Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders

A pharmaceutical product comprising (i) an ErbB inhibitor or a pharmaceutically acceptable salt thereof;

• and (ii) roscovitine or a pharmaceutically acceptable salt thereof;
• wherein the ErbB inhibitor is selected from the group consisting of AG1478, erlotinib, gefitinib, and lapatinib.

A method of treating a proliferative disorder selected from the group consisting of lung cancer, head neck cancer, ovarian cancer and breast cancer, said method comprising simultaneously, sequentially or separately administering to a subject having said proliferative disorder (i) an ErbB inhibitor or a pharmaceutically acceptable salt thereof;

• and (ii) roscovitine or a pharmaceutically acceptable salt thereof;
• wherein the ErbB inhibitor is selected from the group consisting of AG1478, erlotinib, gefitinib, and lapatinib.

A kit of parts comprising:

• (i) an ErbB inhibitor or a pharmaceutically acceptable salt thereof;
• and (ii) roscovitine or a pharmaceutically acceptable salt thereof;
• wherein the ErbB inhibitor is selected from the group consisting of AG1478, erlotinib, gefitinib, and lapatinib.